知镜 Cognispect · 医学文献与研究工作台

Efficacy, Safety, and Pharmacokinetics of Macitentan in Japanese Pediatric Patients With Pulmonary Arterial Hypertension: Prospective, Multicenter, Open-Label Study.

Inuzuka R, Ishii T, Iwasa T, Kurosaki KI, Kuraoka A, Narita J, Takatsuki S, Nakano M, Inagaki R, Mihoya M, Hyunsoo K, Shibuya M, Kobayashi T, Ishida H, Kato T, Miura M, Yamagishi H, Doi S.
Circulation reports · 2026-06-16 · PMID 42577624

文献摘要

Background Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR), imposing an increased workload on the right ventricle and ultimately leading to right heart failure. Macitentan is a potent dual endothelin receptor antagonist that blocks both endothelin receptor subtypes A and B, and is approved for adult patients with PAH, but evidence in pediatric PAH patients is limited. Methods and results This was an open-label, multicenter, Phase III study enrolling Japanese pediatric PAH patients aged ≥3 months to Conclusions Macitentan showed clinically meaningful reduction in PVRI and improved pulmonary hemodynamics in Japanese pediatric patients with PAH, with a favorable safety profile over 52 weeks of treatment.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。